<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Dalbavancin: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Dalbavancin: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Dalbavancin: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="95643" href="/d/html/95643.html" rel="external">see "Dalbavancin: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="121651" href="/d/html/121651.html" rel="external">see "Dalbavancin: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F25184320"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Dalvance</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F55859571"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Xydalba</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F24932710"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Glycopeptide</li></ul></div>
<div class="block doa drugH1Div" id="F25334663"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2fae4cfb-934a-4756-86bc-073fe437156b">Endocarditis, treatment, step-down therapy in patients who inject drugs</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endocarditis, treatment, step-down therapy in patients who inject drugs (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Not first-line treatment; based on expert opinion. Reserve use for patients who inject drugs who had initial clinical improvement with IV treatment for <i>S. aureus</i> infection but cannot complete IV standard of care therapy and are unable to absorb oral antibiotics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36043414']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36043414'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV: </b>1 g as a single dose, followed by 500 mg weekly or 1.5 g as a single dose followed by 1 g every other week for a total duration, including initial IV therapy, of 6 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36043414']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36043414'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5fe294fd-4626-4e48-9579-84675accedc8">Skin and soft tissue infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and soft tissue infection (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Reserve for patients with or at risk for methicillin-resistant <i>S. aureus </i>infection who cannot receive preferred agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27354809']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27354809'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 1.5 g as a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26611777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26611777'])">Ref</a></span>) <b>or </b>1 g as a single dose initially, followed by 500 mg as a single dose 1 week later (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24897082','lexi-content-ref-16231250']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24897082','lexi-content-ref-16231250'])">Ref</a></span>); the single dose has been shown to be as effective as the two-dose regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26611777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26611777'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990263"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">CrCl ≥30 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl &lt;30 mL/minute (not on regularly scheduled dialysis):</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Single-dose regimen:</i> 1.125 g as a single dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Two-dose regimen:</i> 750 mg as a single dose initially, followed by 375 mg as a single dose 1 week later.</p>
<p style="text-indent:-2em;margin-left:2em;">End-stage renal disease patients receiving intermittent hemodialysis (regularly scheduled): No dosage adjustment necessary; administer without regard to timing of hemodialysis.</p></div>
<div class="block doha drugH1Div" id="F50987450"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild impairment (Child-Pugh class A): No dosage adjustment necessary. </p>
<p style="text-indent:-2em;margin-left:2em;">Moderate or severe impairment (Child-Pugh class B or C):  There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied); use with caution.</p></div>
<div class="block doe drugH1Div" id="F25334664"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F53199950"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="121651" href="/d/html/121651.html" rel="external">see "Dalbavancin: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5fe294fd-4626-4e48-9579-84675accedc8">Skin and soft tissue infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and soft tissue infection: </b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children &lt;6 years: IV: 22.5 mg/kg as a single dose; maximum dose: 1,500 mg/dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥6 years and Adolescents: IV: 18 mg/kg as a single dose; maximum dose: 1,500 mg/dose.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F53199954"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Infants, Children, and Adolescents: IV:</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥30 mL/minute/1.73 m<sup>2</sup>: No adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;30 mL/minute/1.73 m<sup>2</sup>: There are no pediatric-specific dosage adjustments provided in the manufacturer's labeling (has not been studied); however, adult pharmacokinetic information shows a decrease in clearance by 47% in patients with CrCl of &lt;30 mL/minute; based on adult recommendations, dosage adjustment may be necessary in patients with CrCl &lt;30 mL/minute not on regularly scheduled dialysis.</p>
<p style="text-indent:-2em;margin-left:2em;">Hemodialysis: &lt;6% removed by 3 hour dialysis session. There are no pediatric-specific dosage adjustments provided in the manufacturer's labeling (has not been studied); in adults with end-stage kidney disease receiving regularly scheduled hemodialysis, no adjustment is necessary and may administer without regards to timing of dialysis.</p></div>
<div class="block dohp drugH1Div" id="F53199955"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Infants, Children, and Adolescents: IV:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild impairment (Child-Pugh class A): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate or severe impairment (Child-Pugh class B or C): There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); use with caution.</p></div>
<div class="block adr drugH1Div" id="F25184036"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions are for adults unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Flushing (&lt;2%), phlebitis (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (2%), skin rash (3%), urticaria (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypoglycemia (&lt;2%), increased gamma-glutamyl transferase (&lt;2%), increased lactate dehydrogenase (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (&lt;2%), <i>Clostridioides difficile</i> colitis (&lt;2%), diarrhea (4%), gastrointestinal hemorrhage (&lt;2%), hematochezia (&lt;2%), melena (&lt;2%), nausea (6%), oral candidiasis (&lt;2%), vomiting (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Vulvovaginal infection (mycotic; &lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Acute posthemorrhagic anemia (&lt;2%), anemia (&lt;2%), eosinophilia (&lt;2%), hematoma (spontaneous; &lt;2%), increased INR (&lt;2%), leukopenia (&lt;2%), neutropenia (&lt;2%), petechia (&lt;2%), thrombocythemia (&lt;2%), thrombocytopenia (&lt;2%), wound hemorrhage (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatotoxicity (&lt;2%), increased serum alkaline phosphatase (&lt;2%), increased serum transaminases (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (&lt;2%), headache (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchospasm (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (pediatric patients: 1%), infusion related reaction (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Hepatic: Increased serum alanine aminotransferase (&gt;3 x ULN)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: <i>Clostridioides difficile</i>-associated diarrhea</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain</p></div>
<div class="block coi drugH1Div" id="F24932712"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to dalbavancin or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F25334262"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic effects: Patients with normal baseline transaminase levels may have ALT elevation &gt;3 times the upper limit of normal (ULN) during therapy; in clinical studies, abnormalities in liver tests (ALT, AST, bilirubin) were reported with similar frequency in the dalbavancin and comparator arms. ALT elevations were reversible after discontinuation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Serious hypersensitivity (anaphylactic) and skin reactions have been reported with dalbavancin. Discontinue treatment if an allergic reaction occurs. Dalbavancin cross-sensitivity to other glycopeptides may occur; exercise caution in patients with a history of glycopeptide allergy; carefully screen for previous hypersensitivity reactions to glycopeptides prior to administration.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infusion reactions: Rapid intravenous infusions of dalbavancin (&lt;30 minutes) may cause reactions that resemble vancomycin infusion reaction (formerly "red man syndrome") (eg, flushing of the upper body, urticaria, pruritus, rash). Stopping or slowing the infusion may result in cessation of these reactions (Alvarez-Arango 2021).</p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Use may result in fungal or bacterial superinfection, including <i>Clostridioides</i>
<i>difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with moderate to severe hepatic impairment (Child-Pugh class B or C).</p></div>
<div class="block foc drugH1Div" id="F25184321"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Dalvance: 500 mg (1 ea)</p></div>
<div class="block geq drugH1Div" id="F25184319"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F25211462"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Dalvance Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $2,134.96</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F55859572"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xydalba: 500 mg (1 ea) [contains lactose monohydrate]</p></div>
<div class="block adm drugH1Div" id="F25334668"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">IV: Infuse over 30 minutes. If a common IV line is being used to administer other drugs in addition to dalbavancin, the line should be flushed before and after each infusion with D5W.</p></div>
<div class="block admp drugH1Div" id="F53199957"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: IV: Infuse over 30 minutes. If a common IV line is being used to administer other drugs in addition to dalbavancin, the line should be flushed before and after each infusion with D5W.</p></div>
<div class="block uica drugH1Div" id="F25334671"><span class="drugH1">Usual Infusion Concentrations: Adult</span>
<p style="text-indent:0em;">
<i>IV infusion:</i> 500 to 1,500 mg in 100 to 1,500 mL (concentration of 1 to 5 mg/mL) of D5W. </p></div>
<div class="block use drugH1Div" id="F24932711"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Skin and soft tissue infections:</b> Treatment of adult and pediatric patients with acute bacterial skin and soft tissue infections caused by susceptible isolates of the following gram-positive microorganisms: <i>Staphylococcus aureus</i> (including methicillin-susceptible and methicillin-resistant isolates), <i>Streptococcus pyogenes</i>, <i>Streptococcus agalactiae</i>, <i>S. dysgalactiae</i>, <i>Streptococcus anginosus</i> group (including <i>S. anginosus</i>, <i>S. intermedius</i>, <i>S. constellatus</i>), and <i>Enterococcus faecalis</i> (vancomycin-susceptible isolates).</p></div>
<div class="block off-label drugH1Div" id="F58692787"><span class="drugH1">Use: Off-Label: Adult</span><p>Endocarditis, treatment, step-down therapy in patients who inject drugs:</p></div>
<div class="block cyt drugH1Div" id="F24958077"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F24958074"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F25334259"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Adverse events have been observed in animal reproduction studies.</p>
<p style="text-indent:0em;">Information related to dalbavancin in pregnancy is limited. A case report describes use of dalbavancin for ~4 weeks during the last month of pregnancy for the treatment of methicillin-resistant <i>S. aureus</i> endocarditis<i>. </i>Treatment was unsuccessful. Following therapy, blood cultures grew vancomycin-intermediate <i>S. aureus</i> requiring treatment with multiple antibiotics (Steele 2018). The long half-life of dalbavancin should be considered when evaluating potential exposure to the fetus.</p></div>
<div class="block brc drugH1Div" id="F25334261"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if dalbavancin is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">A case report describes use of dalbavancin in a lactating patient who presented with mammary dysbiosis and multiple nipple blebs 6 months postpartum. Breast milk cultures were positive for multidrug-resistant methicillin-resistant <i>S. aureus. </i>The patient received 2 doses of dalbavancin, the first at 6 months postpartum and the second 2 weeks later. Breast milk cultures were negative at 7 months postpartum. The child was exclusively fed expressed breast milk prior to and throughout dalbavancin therapy. Adverse events were not observed in the mother or infant (Mitchell 2020).</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F25334672"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Baseline BUN, serum creatinine, and liver function tests (AST, ALT, bilirubin). Monitor patients for any infusion-related reactions and for superinfection during therapy.</p></div>
<div class="block pha drugH1Div" id="F25334409"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Dalbavancin is a lipoglycopeptide which binds to the D-alanyl-D-alanine terminus of the stem pentapeptide in nascent cell wall peptidoglycan, preventing cross-linking and interfering with cell wall synthesis. It is bactericidal in vitro against <i>Staphylococcus aureus</i> and <i>Streptococcus pyogenes</i></p></div>
<div class="block phk drugH1Div" id="F25334544"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 7 to 13 L (Leighton, 2004)</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 93% (primarily to albumin)</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Minor metabolite (hydroxy-dalbavancin)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 346 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (33% as unchanged drug, 12% as hydroxy metabolite); feces (20%) </p></div>
<div class="block phksp drugH1Div" id="F51220883"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Mean plasma clearance reduced 11%, 35%, and 47% in subjects with mild (CrCl 50 to 79 mL/minute), moderate (CrCl 30 to 49 mL/minute), and severe (CrCl &lt;30 mL/minute) renal impairment, respectively.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Mean AUC<sub>0-336 hrs</sub> decreased 28% and 31% in Child-Pugh class B and C patients, respectively.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F46047359"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Xydalba</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Xydalba</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Xydalba</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Xydalba</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Xydalba</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Xydalba</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Xydalba</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Xydalba</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Xydalba</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Xydalba</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Xydalba</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Xydalba</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Dalvance</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Xydalba</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Xydalba</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Xydalba</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Xydalba</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Xydalba</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Xydalba</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-33830710">
<a name="33830710"></a>Alvarez-Arango S, Ogunwole SM, Sequist TD, Burk CM, Blumenthal KG. Vancomycin infusion reaction - moving beyond "red man syndrome". <i>N Engl J Med</i>. 2021;384(14):1283-1286. doi:10.1056/NEJMp2031891<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dalbavancin-drug-information/abstract-text/33830710/pubmed" id="33830710" target="_blank">33830710</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36043414">
<a name="36043414"></a>Baddour LM, Weimer MB, Wurcel AG, et al; American Heart Association Rheumatic Fever, Endocarditis and Kawasaki Disease Committee of the Council on Lifelong Congenital Heart Disease and Heart Health in the Young; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; and Council on Peripheral Vascular Disease. Management of Infective Endocarditis in People Who Inject Drugs: A Scientific Statement From the American Heart Association. <i>Circulation</i>. 2022;146(14):e187-e201. doi:10.1161/CIR.0000000000001090<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dalbavancin-drug-information/abstract-text/36043414/pubmed" id="36043414" target="_blank">36043414</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24897082">
<a name="24897082"></a>Boucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW. Once-weekly dalbavancin versus daily conventional therapy for skin infection. <i>N Engl J Med</i>. 2014;370(23):2169-2179. doi:10.1056/NEJMoa1310480<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dalbavancin-drug-information/abstract-text/24897082/pubmed" id="24897082" target="_blank">24897082</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dalvance.1">
<a name="Dalvance.1"></a>Dalvance (dalbavancin) [prescribing information]. Madison, NJ: Allergan USA; July 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dalvance.2">
<a name="Dalvance.2"></a>Dalvance (dalbavancin) [prescribing information]. Parsippany, NJ: Durata Therapeutics; October 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26611777">
<a name="26611777"></a>Dunne MW, Puttagunta S, Giordano P, Krievins D, Zelasky M, Baldassarre J. A randomized clinical trial of single-dose versus weekly dalbavancin for treatment of acute bacterial skin and skin structure infection. <i>Clin Infect Dis</i>. 2016;62(5):545-551. doi:10.1093/cid/civ982<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dalbavancin-drug-information/abstract-text/26611777/pubmed" id="26611777" target="_blank">26611777</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16231250">
<a name="16231250"></a>Jauregui LE, Babazadeh S, Seltzer E, et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. <i>Clin Infect Dis</i>. 2005;41(10):1407-1415.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dalbavancin-drug-information/abstract-text/16231250/pubmed" id="16231250" target="_blank">16231250</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14982787">
<a name="14982787"></a>Leighton A, Gottlieb AB, Dorr MB, et al. Tolerability, pharmacokinetics and serum bactericidal activity of intravenous dalbavancin in healthy volunteers. <i>Antimicrob Agents Chemother</i>. 2004;48(3):940-945.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dalbavancin-drug-information/abstract-text/14982787/pubmed" id="14982787" target="_blank">14982787</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27354809">
<a name="27354809"></a>Leuthner KD, Buechler KA, Kogan D, Saguros A, Lee HS. Clinical efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI). <i>Ther Clin Risk Manag.</i> 2016;12:931-940. doi:10.2147/TCRM.S86330<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dalbavancin-drug-information/abstract-text/27354809/pubmed" id="27354809" target="_blank">27354809</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31310726">
<a name="31310726"></a>Mitchell KB, Eglash A, Bamberger ET. Mammary dysbiosis and nipple blebs treated with intravenous daptomycin and dalbavancin. <i>J Hum Lact.</i> 2020;36(2):365-368. doi:10.1177/0890334419862214<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dalbavancin-drug-information/abstract-text/31310726/pubmed" id="31310726" target="_blank">31310726</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15668859">
<a name="15668859"></a>Raad I, Darouiche R, Vazquez J, et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. <i>Clin Infect Dis</i>. 2005;40(3):374-380.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dalbavancin-drug-information/abstract-text/15668859/pubmed" id="15668859" target="_blank">15668859</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14583862">
<a name="14583862"></a>Seltzer E, Dorr MB, Goldstein BP, Perry M, Dowell JA, Henkel T; Dalbavancin Skin and Soft-Tissue Infection Study Group. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. <i>Clin Infect Dis</i>. 2003;37(10):1298-1303.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dalbavancin-drug-information/abstract-text/14583862/pubmed" id="14583862" target="_blank">14583862</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28628223">
<a name="28628223"></a>Steele JM, Seabury RW, Hale CM, Mogle BT. Unsuccessful treatment of methicillin-resistant Staphylococcus aureus endocarditis with dalbavancin. <i>J Clin Pharm Ther.</i> 2018;43(1):101-103. doi:10.1111/jcpt.12580<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dalbavancin-drug-information/abstract-text/28628223/pubmed" id="28628223" target="_blank">28628223</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Xydalba.1">
<a name="Xydalba.1"></a>Xydalba (dalbavancin) [product monograph]. Mississauga, Ontario, Canada: Cipher Pharmaceuticals Inc; August 2018.</div>
</li></ol></div><div id="topicVersionRevision">Topic 95502 Version 123.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
